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Objectives. To assess the psychometric attributes of the Apathy Scale- (AS-) Spanish version in patients with advanced Parkinson’s
disease (APD).Materials andMethods. Over 6months, 61 patients participated in a clinical study of levodopa-carbidopa intestinal
gel (LCIG) and were evaluated using the AS and other clinical tools. Various psychometric attributes of the AS were assessed.
Results. Patients (60.7% men) were aged 68.02± 7.43 years, with 12.57± 5.97 years from PD diagnosis. Median HY of patients in
“on state” was 2 (range, 1–4), and mean levodopa equivalent daily dose was 1455.98± 456.00mg. Overall, the parameters of
feasibility/acceptability were satisfactory, except for a moderate-to-high floor effect in AS items but not in its total score (both
3.3%). Cronbach’s alpha was 0.78, while item homogeneity coefficient was 0.21. Almost all items (11/14) reached acceptable item-
total corrected correlations (rS � 0.16–0.50). AS total score was moderately correlated with Beck Depression Inventory (0.34) and
with Non-Motor Symptoms Scale domains 2 (sleep/fatigue, 0.35), 3 (mood/apathy, 0.56), and 5 (attention/memory, 0.41). ,ere
were no significant differences between AS total scores by established groups of sex, time from diagnosis, HY, and Clinical Global
Impression-Severity Scale. Following LCIG treatment, there was no significant change in the AS total score. ,e relative change
was 5.56%, the standard error of the difference was 4.17, and Cohen’s d effect was 0.10. Conclusions. ,e AS showed satisfactory
feasibility, acceptability, scaling assumptions, internal consistency, and convergent validity. Responsiveness parameters were
poor, probably due to the characteristics of the clinical study from which these data came. ,is trial is registered
with NCT02289729.
1. Introduction
Apathy, a syndrome defined by an overall lack of interest and
motivation in emotional, cognitive, and goal-directed be-
havior, [1] is a nonmotor symptom frequently associated
with various medical disorders, including Parkinson’s dis-
ease (PD). Its prevalence in healthy elderly populations has
been proposed to be up to 20%, but it reaches around 40%
(range, 34.6%–45.0%) in those with Parkinson’s disease (PD)
[2]. Findings suggest that apathy in patients with PD may be
directly related to the physiological changes of PD rather
than psychological reactions or adaptation to illness. It has
been hypothesized that apathy in PD may be caused by
dopamine deficiency in the limbic areas of the brain al-
though its pathophysiology is probably complex and het-
erogeneous [1, 2].
Apathy has been shown to reduce goal-directed be-
haviors and emotional reactivity, causing less adherence to
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treatments, faster cognitive decline, lower quality of life
(QoL), functional impairment, and increased caregiver
burden [3, 4].
To accurately assess this burdensome nonmotor symptom
in PD, the Apathy Scale (AS) was created [5]. ,e AS is a 14-
question inventory that evaluates the domains of apathy
related to cognition, motivation, and interest. It has shown
satisfactory psychometric properties in PD and has been
recommended for screening apathy and evaluating its severity
in this context [6]; however, it has not yet been validated for
use in either the advanced PD (APD) population or in the
Spanish population. ,erefore, the objective of this study was
to assess the psychometric attributes of the AS-Spanish
version in a sample of Spanish patients with APD.
2. Materials and Methods
2.1. Design. Data for the present study are derived from the
ADEQUA study (this trial is registered with NCT02289729),
an observational, single-arm, postmarketing, nationwide,
multicenter clinical study that was carried out in patients
with APD with an indication for levodopa-carbidopa in-
testinal gel (LCIG) [7].
2.2. Patients. Inclusion criteria were as follows: (1) APD
designation by a neurologist; (2) indication for LCIG
according to the drug fact sheet; (3) age ≥18 years; and (4)
signed informed consent. Patients who experienced severe
motor fluctuations and dyskinesia were considered to have
APD if conventional treatment options could not satisfac-
torily manage these complications.
Exclusion criteria were as follows: (1) absence of any
inclusion criteria; (2) cognitive deterioration that could
impede the accurate completion of questionnaires, con-
firmed by a score of <26 points on the Mini-Mental State
Examination; and (3) contraindication to LCIG, according
to the drug fact sheet of the product.
Considering the objectives of the ADEQUA study, it was
determined that a sample size of 60 patients would be
necessary.,e sample was recruited from November 2014 to
April 2016.
2.3. Ethical Issues. ,e study was conducted in accordance
with the Declaration of Helsinki and with standard oper-
ating procedures that guaranteed compliance with Good
Clinical Practice, as described in the ICH guidelines. ,e
study was evaluated by the Spanish Agency of Medicines and
Medical Devices and was approved by the Spanish auton-
omous communities and the ethics committees of the
participant hospitals. Patients had to be ≥18 years and must
have provided informed consent to participate in the study.
2.4. Assessments. Information regarding age, sex, ethnicity,
civil status, education, employment, time from PD di-
agnosis, and current treatment was collected.
,e AS is a 14-question inventory that is useful in
screening the presence of apathy and determining its severity
over the past 4 weeks. Each question is scored from 0 to 3,
with the total score (range, 0–42) calculated by summing the
scores of every item. Questions 1 through 8 are scored on a
scale from 3 (“not at all”) to 0 (“a lot”), whereas questions 9
through 14 are scored on a scale from 0 (“not at all”) to 3 (“a
lot”). A score of 14 or higher indicates the presence of apathy
in a patient [5]. In addition to the AS, patients completed the
following assessments during this study:
(1) Unified Parkinson’s Disease Rating Scale (UPDRS)
[8], a 4-domain, 42-item evaluative instrument
specific to PD. Domains III (motor examination),
where scores range from 0 to 108, and IV (com-
plications of therapy in the past week), where scores
range from 0 to 23, were used in this study.
(2) Schwab and England Scale (S&E), a common scale
that assesses the capacity to perform activities of
daily living in PD patients in 11 stages from 0%
(completely dependent with vegetative dysfunction,
bedridden) to 100% (completely independent, es-
sentially normal). ,e version included in the
UPDRS was used [8].
(3) Hoehn and Yahr (HY), a classification system that
measures the stages of PD from 1 to 5, with 1 in-
dicating unilateral PD manifestation and 5 in-
dicating the most severe disease [8].
(4) Non-Motor Symptoms Scale (NMSS) [9], a scale
consisting of 30 items that quantitatively evaluates
the burden of nonmotor symptoms in patients with
PD. It takes into account both the severity and
frequency of these symptoms, which are separated
into 9 domains: cardiovascular, sleep/fatigue,
mood/apathy, perceptual problems/hallucinations,
attention/memory, gastrointestinal tract, urinary
function, sexual function, and miscellaneous.
(5) Clinical Global Impression-Severity (CGI-S) Scale
[10], a 7-point scale in which clinicians rate the
severity of a patient’s disease at the time of assess-
ment. ,e ratings range from 1 (“normal, not at all
ill”) to 7 (among the most extremely ill patients”).
(6) Beck Anxiety Inventory (BAI) [11], which is
composed of 21 items scored between 0 and 3. Total
scores are calculated by summing the items, with
higher scores indicating more severe anxiety
symptoms. ,is questionnaire determines the se-
verity of anxiety in patients over the past week.
(7) Beck Depression Inventory II (BDI-II) [12], which
is composed of 21 items that range from 0 to 3 and
that are summed to create a total score, with higher
scores indicating more severe depressive symptoms.
,is assessment measures the severity of depression
over the past 3weeks.
(8) Parkinson’s Fatigue Scale (PFS-16) [13], a 16-item
scale in which each item is scored between 1
(“strongly disagree”) and 5 (“strongly agree”).
Scores range from 16 to 80, with higher scores
indicating higher fatigue severity.
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(9) Parkinson’s Disease Questionnaire-39 (PDQ-39)
[14], a 39-item, patient-completed questionnaire
that assesses QoL in patients with PD. ,ese
items are grouped into 8 dimensions, which
include mobility, activities of daily living, emo-
tional well-being, stigma, social support, cogni-
tive deterioration, communication, and bodily
discomfort.
(10) Zarit Burden Interview (ZBI) [15], an instrument
designed to assess the burden experienced by
caregivers of dependent persons. It consists of 22
items that range from 0 (“never”) to 4 (“nearly
always”) and that, when summed, represent the
level of caregiver burden.
Patient assessment was performed in “ON” state.
Levodopa equivalent daily dose (LEDD) was also calculated
for each patient according to Tomlinson et al. [16].
2.5. Data Analysis. ,e data were anonymized by each
center and were sent to the National Center of Epidemi-
ology, Carlos III Institute of Health, Madrid, Spain.
As shown by the Shapiro–Francia test, the data distri-
bution of the main variables in the study was not normal;
therefore, nonparametric statistics were utilized. To calculate
the AS total score, item scores were summed following the
rules of the scale. For demographic data, χ2 and Mann–
Whitney U tests were conducted to determine whether
significant differences were present between groups.
Data quality and acceptability were calculated for each
item of the AS, as well as for the total score, by determining
the percentage of missing responses, mean, median, stan-
dard deviation, skewness, minimum and maximum values,
and floor and ceiling effects. Concerning data quality,
missing items should have been <5% of the data set. Sim-
ilarly, data acceptability was considered satisfactory when all
possible scores were observed, the mean and median were
close (difference <10% of maximum possible score), floor
and ceiling effects were <15%, and skewness values ranged
from −1 to 1 [17]. Internal consistency was assessed using
Cronbach’s alpha (standard, >0.70) [17], item-total cor-
rected correlation (r≥ 0.30 was deemed acceptable), and
item homogeneity coefficient (standard value, ≥0.15) [18].
Hypotheses testing was carried out using both conver-
gent and known-groups validity. Spearman’s rank correla-
tion coefficients were utilized to analyze the relationship
between AS total score and both the domains and total
scores of the other assessments completed in this study.
Convergent validity was considered high for correlation
coefficients ≥0.60 and moderate for correlations coefficients
between 0.30 and 0.59 [19]. Furthermore, Mann–Whitney
and Kruskal–Wallis tests were used to determine whether
significant differences existed in the AS total score between
groups based on age, sex, time from diagnosis, HY, and CGI-
S (known-groups validity). Based on Fayers and Machin,
these differences were considered significant if the magni-
tude of the difference was evident (e.g., ≥15% of the max-
imum total score) and p< 0.05 [20].
A longitudinal analysis was conducted using the data
collected at follow-up, which took place 6 (±0.5) months
later. AS responsiveness was determined by the magni-
tude of the difference between baseline and follow-up,





) [21], and effect size for paired data between
applications. Effect size was considered small (0.20–0.49),
moderate (0.50–0.79), or large (≥80). In addition, correla-
tion coefficients were obtained to show the association
between the change in the AS total score and the scores of the
other measures in the study.,e data analysis was conducted
using IBM SPSS (Version 24; IBM Corp, Armonk, NY).
3. Results
At baseline, our sample included 61 patients and was
composed of 37 (60.7%) men, with a mean age of
68.02± 7.43 (range, 50–81) years. Patients were diagnosed
with PD 12.57± 5.97 (range, 4–37) years ago. Most patients
were married/partnered (77.05%) and retired (78.7%), and
their predominant level of education was basic or less
(77.0%). ,e median HY stage of patients in the “on state”
was 2 (interquartile range, 1-2), with 44.26% of patients in
stage 1, 42.62% in stage 2, 11.48% in stage 3, and 1.64% in
stage 4. Concerning the CGI-S (median, 3; range, 1–4), most
patients had a score of 3 (75.41%) or 4 (14.75%); however,
scores of 1 (1.64%) and 2 (8.20%) were also represented. One
patient did not complete the AS and, therefore, the final
sample was of 60 patients. Table 1 shows the descriptive
statistics for the applied measures.
For AS items, there was only one missing datum
(0.12%), which was imputed by the mean of the in-
dividual’s observed values. Concerning item-related ac-
ceptability, all possible scores were observed in the
sample, except in items 2 and 4. ,e standard deviation of
items ranged from 0.62 to 1.06, and they showed a
moderate-to-high floor effect (Table 2). Most item scores
remained in the accepted range of skewness (−1 to +1) or
were marginally outside (up to an excess of |0.81| points).
,e mean AS total score was 11.55 ± 6.49 (median, 10;
range, 1–24), with negligible floor and ceiling effects
(both, 3.3%) and a skewness value of 0.32 (Table 2). ,e
cutoff of ≥14 points indicative of apathy [5] was reached
by 36.7% of the sample.
Regarding internal consistency, Cronbach’s alpha was
0.78, while item homogeneity coefficient was 0.21. As shown
in Table 3, almost all items (11/14) reached item-total
corrected correlations above the criterion 0.30, except for
items 3 (0.16), 4 (0.22), and 13 (0.21).
,e AS total score was moderately correlated with age
(rS � 0.32); NMSS items 7 (loss of interest in the patient’s
surroundings, 0.38) and 8 (loss of interest in doing things or
lack of motivation to start new activities, 0.56); NMSS do-
mains 2 (sleep/fatigue, 0.35), 3 (mood/apathy, 0.56), and 5
(attention/memory, 0.41); NMSS total score (0.49); and BDI-
II (0.34). However, its associations with the rest of the PD-
related measures were weak or negligible. Moreover, there
were no significant differences between AS total scores by
established groups of sex, time from diagnosis (<10 years,
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10–15 years, >15 years, based on percentiles and tabulation),
HY, and CGI-S.
In addition, longitudinal analysis of 53 patients who
completed the study showed significant improvements
in the conditions assessed by the quantitative instruments
utilized in this study between baseline and follow-up,
except for the AS and ZBI (Table 4). ,e relative change
between applications for the AS was 5.56%, the standard
error of the difference was 4.17, and Cohen’s d effect was
0.10. Correlations between the change in AS and the
change in other measures were moderate for NMSS
(rS � 0.56) and for PDQ-39 and UPDRS IV (both,
rS � 0.31), but they were weak for the others
(rS � |0.01 – 0.21|).
4. Discussion
,is is the first attempt to validate the Spanish version of the
AS in patients with APD.,e original English version, which
is an adaptation of the Apathy Evaluation Scale, acceptably
Table 1: Descriptive statistics of other measures in the study.
Measures Mean SD Min Max
Beck Anxiety Inventory 19.77 9.24 0 41
Beck Depression Inventory-II 18.11 9.34 1 46
Schwab and England Scale (“on state”) 69.84 23.77 10 100
Non-Motor Symptoms Scale-total score 83.05 32.07 29 167
Cardiovascular (including falls) 2.41 3.53 0 14
Sleep/fatigue 16.87 7.63 0 40
Mood/cognition 15.69 13.93 0 56
Perceptual problems/hallucinations 3.08 5.53 0 25
Attention/memory 5.80 6.11 0 24
Gastrointestinal tract 7.44 6.23 0 24
Urinary 12.44 9.59 0 36
Sexual function 7.80 8.16 0 24
Miscellaneous 11.51 8.68 0 36
PDQ-39 (summary index) 46.13 13.81 10.90 85.90
Mobility 66.88 22.31 2.50 100.00
Activities of daily living 54.65 24.48 4.17 95.83
Emotional well-being 47.92 21.70 4.17 100.00
Stigma 20.10 22.61 0 93.75
Social support 18.89 24.49 0 100.00
Cognitions 36.35 20.89 0 93.75
Communication 31.81 24.67 0 100.00
Bodily discomfort 45.69 20.73 0 100.00
Parkinson Fatigue Scale (PFS-16) 58.71 12.43 18.00 78.00
UPDRS-motor examination 30.05 14.06 4 58
UPDRS-complications 8.62 2.87 3 15
Zarit Burden Interview 25.30 13.47 4 64
Levodopa equivalent daily dose (mg) 1455.98 456.00 478.00 3110.00
Max, maximum; Min, minimum; PDQ-39, Parkinson’s Disease Questionnaire-39 Items; SD, standard deviation; UPDRS, Unified Parkinson’s Disease Rating
Scale.
Table 2: Acceptability data of the apathy scale.
Item Min Max Mean SD Median Floor (%) Ceiling (%) Skew
1. Interested in learning? 0 3 0.92 0.98 1 45.0 6.7 0.60
2. Anything interest you? 0 2 0.45 0.62 0 61.7 0.0 1.04
3. Concern about your condition? 0 3 0.38 0.74 0 75.0 1.7 1.81
4. Much effort into things? 0 2 0.42 0.70 0 70.0 0.0 1.37
5. Looking for something to do? 0 3 0.80 1.02 0 53.3 10.0 0.98
6. Plans and goals for the future? 0 3 1.42 1.06 1 23.3 20.0 0.13
7. Do you have motivation? 0 3 1.00 1.03 1 43.3 8.3 0.48
8. Energy for daily activities? 0 3 1.33 0.86 1 20.0 5.0 −0.21
9. Someone tells you what to do? 0 3 0.62 0.96 0 65.0 6.7 1.30
10. Indifferent to things? 0 3 0.62 0.83 0 58.3 1.7 0.99
11. Unconcerned with things? 0 3 1.00 0.96 1 35.0 10.0 0.70
12. Need to be pushed? 0 3 0.87 0.98 1 46.7 8.3 0.81
13. Neither happy nor sad? 0 3 1.23 1.00 1 26.7 13.3 0.35
14. Consider yourself apathetic? 0 3 0.50 0.85 0 70.0 3.3 1.48
Total score 1 24 11.55 6.49 10 3.3 3.3 0.32
Max, maximum; Min, minimum; SD, standard deviation; Skew, skewness.
4 Parkinson’s Disease
represents the cognitive, behavioral, and affective domains
of the construct of apathy [22, 23].
,e present study showed satisfactory AS data quality
(99.9% of data available) and scaling assumptions, consid-
ering the range of item score distributions as a whole. A
moderate-to-high floor effect was present for most items,
due to the absence of the corresponding symptom in that
proportion of patients. Although no one had an AS total
score of 0, only 36.7% of patients were diagnosed with
apathy by the scale (Table 2). Floor and ceiling effects were
slight for the total score, which showed skewness in the
standard range. ,ese results indicate appropriate feasibility
and acceptability of the scale, yet they could not be compared
with other studies, as this analysis has not been previously
conducted to the best of our knowledge.
,e internal consistency of the AS was satisfactory as a
whole, with Cronbach’s alpha higher than the threshold
value and close to values from previous studies in regular
and early PD patients (alpha, 0.69–0.83) [5, 23, 24]. Notably,
item 3 showed the lowest item-total correlation (rS � 0.16,
Table 3), a finding in line with previous studies that showed
low interitem correlation or effect indicator for this item
[23, 25].
Our results showed that there were moderate associa-
tions between AS total score and the apathy-specific ques-
tions of the NMSS, items 7 and 8. ,ese apathy-specific
questions inquire about the loss of interest in the patient’s
surroundings and loss of interest in doing things or the lack
of motivation to start new activities. As these are aspects
characteristic to apathy, it follows that the AS total score
would be significantly correlated with these items although
there are clear differences among these assessments in their
structure and content. Overall, a moderate correlation was
found between AS and NMSS total score. ,is association
could be explained by the inclusion of NMSS domains
specific to sleep/fatigue (domain 2), mood/apathy (domain
3), and attention/memory (domain 5) and disorders that
have been shown to be associated with apathy [1, 26, 27].
However, the AS showed weak-to-moderate correlations
with the BDI-II, PFS-16, and NMSS domain 2 (sleep/
fatigue), suggesting a relatively loose relationship between
apathy, depression, and fatigue in our sample. Although
apathy is often combined with depression and fatigue, they
are separate disturbances [24, 28].
In PD, moderate or high associations have been observed
between the AS, including a reduced 11-item version, and
depression measures [24, 25, 29, 30]. Nonetheless, a close
correlation between apathy and depression is not universally
observed [23, 26], and other studies had findings like ours
regarding depression using different scales [31].
Similarly, an overlap between apathy and fatigue has
been recognized although they are distinct disorders
[32, 33]. A significant association between fatigue and apathy
or specific apathy-related domains was observed in several
studies [31, 34–36] but not in others [37]. ,e differences
with the present study related to the sample (patients with
APD) and the applied measures (the AS and PFS-16) make it
difficult to compare the results. A similar situation occurs
with the combination of sleep disorder and fatigue, with
studies using different sample composition and measures
[31, 36].
Findings from other studies do, however, confirm lower
cognitive functioning in reference to attention and memory
in PD, with higher levels of apathy in patients with cognitive
impairment [38, 39]. Starkstein et al. demonstrated that
patients with PD diagnosed with apathy according to the AS
performed worse on time-dependent cognitive tasks than
normal participants [5].
Due to the deficits in attention, memory, and concen-
tration found in apathetic patients with PD, it had previously
been proposed that apathy may be related to bradyphrenia
and, thus, an alteration in catecholaminergic metabolism
[5]. However, more recent studies have suggested that the
presence of Lewy body and/or Alzheimer’s pathology in
these patients may lead to errors in memory encoding and
retrieval [38]. Additional research is needed to definitively
establish the relationship between apathy, depression, and
cognitive impairment [40].
Previous research has also suggested that apathy is re-
lated to QoL [29], although the correlation between AS and
PDQ-39 in that particular study was substantially higher
than ours (rS � 0.51 vs. 0.09), despite similar correlations
between AS and UPDRS III, UPDRS IV, patient age, time
from PD diagnosis, and LEDD in both studies. We can only
explain this discrepancy due to the difference between
samples: consecutive patients in the study by Oguru et al.
[29] and patients with APD in ours.
Furthermore, the AS total score did not differ signifi-
cantly between the known groups tested. ,is would suggest
that apathy is not directly related to sex, time since PD
diagnosis, HY stage, and illness severity levels (CGI-S).
Although the presence of apathy has been associated with
shorter time since PD diagnosis, earlier HY stages, and lower
LEDD, these results were again observed in samples with
patients in the earlier stages of PD [41]. Cognitive perfor-
mance is also linked with level of education. In this study, the
majority of participants had only a basic level of education
that may have an influence in the apathy score.
Contrary to our findings in which the AS total score did
not differ significantly following LCIG treatment, previous
Table 3: Corrected item-total correlations.
Item Coefficient∗
1. Interested in learning? 0.48
2. Anything interest you? 0.49
3. Concern about your condition? 0.16
4. Much effort into things? 0.22
5. Looking for something to do? 0.50
6. Plans and goals for the future? 0.44
7. Do you have motivation? 0.46
8. Energy for daily activities? 0.47
9. Someone tells you what to do? 0.31
10. Indifferent to things? 0.45
11. Unconcerned with things? 0.46
12. Need to be pushed? 0.46
13. Neither happy nor sad? 0.21
14. Consider yourself apathetic? 0.48
∗Spearman’s rank correlation coefficient.
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research has shown that levodopa and dopamine agonists
may lessen the burden of apathy in patients with PD, as a
dopaminergic deficit could contribute to the development of
apathy; however, it is important to note that the patho-
physiology of apathy is multifactorial in nature [1, 28]. If
LCIG was an efficacious treatment for apathy, our longi-
tudinal analysis showed poor responsiveness for the AS, with
a standard error of the difference clearly higher than the
mean difference between baseline and follow-up, a negligible
effect size, small relative change, and weak or moderate
correlations with changes in other clinical variables.
,e primary limitation of our study is that it was not
designed as a scale validation study but rather as a clinical
study. ,erefore, the study was limited by the lack of a gold
standard to accurately assess the presence or absence of apathy
in our patients with APD and to conduct a sensitivity and
specificity analysis. Starkstein and colleagues reported a sen-
sitivity of 66% and a specificity of 100% in their original sample
using neurologist clinical impressions as their gold standard
[5]; future researchwarrants a sound evaluation of thismeasure
[34]. Using a Spanish version of the scale, our paper presents
the first validation of the AS in patients with APD and a
complementary assessment of this important clinical tool.
5. Conclusions
,e AS as a whole showed satisfactory feasibility, accept-
ability, scaling assumptions, internal consistency, and
convergent validity. Responsiveness parameters were poor,
but data came from a clinical study of patients with APD
with a nonspecific therapy for treating apathy, making it
difficult to judge this psychometric attribute.
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Burgos Hospital Center: Esther Cubo; Arquitecto Marcide
Hospital: Diego Santos; Son Espases Hospital: Bárbara Vives;
Puerta del Mar Hospital: Miguel Moya and Raúl Espinosa
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